Report Overview
Summary
After years of buoyant growth, the pharmaceutical industry is facing up to a more challenging time. With the growing cost of developing novel drugs, combined with rising regulatory pressures, the use of lifecycle management is playing an ever-more important role in the increasingly cost-conscious pharma industry. This report identifies actual opportunities in OTC switching.
Key Findings
The pharmaceutical market is changing. Since 2007, sales of OTC drugs have outstripped those for their prescription counterparts. Whereas once consumer health products were seen as a lucrative sideline, they are becoming a major focus for pharmaceutical companies. Between 2008 and 2013, worldwide OTC growth averaged 6.5% compared to 4.5% for Rx.
Creating new categories can be fraught with risk. This was shown by the attempts of GSK to introduce the weight-loss therapy area with its Alli (orlistat 60mg capsules). After a promising start, sales collapsed due to concerns over both efficacy and safety.
With a large and rapidly expanding population, Indonesia is catching the eye of Western multinationals in a number of industries. Within the pharma industry, self-medication is well established and these drugs account for 40% of drug spending.
Synopsis
This report takes an in-depth look at the market for Rx-OTC switches. It considers which categories have the most potential for switching, analyzing both past performance and expected future outcomes, and then examines specific candidates.
Reasons To Buy
Identify products that have the most Rx-OTC switching potential.
Analyze the product categories that are changing the Rx-OTC environment.
Understand why some key Rx-OTC switches have failed.
Use case studies to assess the revenues generated by successful switches.
Table Of Contents
Table Of Contents
List Of Tables
List Of Figures